Magda Mensi
Brescia, Lombardy, 25123, Italy
NCT Number: NCT07482280
Enamel is the most calcified tissue in the body and is composed of 92-96% by organic substances in particular hydroxyapatite. Hydroxyapatite nanoparticles are similar to the morphology and structure of tooth enamel apatite crystals and has been studied as a biomimetic material for enamel remineralization. Dentin hypersensitivity is a very common disorder in the adult population and it is characterized by short and intensive pain, in response to thermal or chemical stimuli. Dentin hypersensitivity can be generalized or localized, it can simultaneously affect one or more tooth surfaces and depends on the duration of the stimulus applied. In addition, there are numerous factors that can affect this condition, including gum recessions, enamel erosion, dentin exposure and periodontal disease. Many patients suffer from hypersensitivity during professional oral hygiene. The Vector system (Durr Dental, Bietigheim-Bissin gen, Germany) generates ultrasonic vibrations at a frequency of 25 kHz, which are converted by a resonant ring in a horizontal oscillation that is deflected vertically. In particular, the Vector Polish handpiece with a solution of hydroxyapatite is activated through ultrasound and it has the ability to favor the occlusion of the dentinal tubules leading to a reduction in hypersensitivity. The tip of the handpiece moves parallel along the axis of the insert, suitable for use in combination with the polishing fluid containing hydroxyapatite. The presence of this fluid associated with ultrasonic allows the root biofilm to be broken down thanks to cavitation and hydrodynamic forces; furthermore, avoiding horizontal vibrations caused a lower hypersensitivity compared to manual instruments. The aim of this randomized, controlled, split-mouth study is to investigate whether this device is effective in maintaining periodontal patients and is more gentle and comfortable during treatment, specifically in reducing sensitivity.
To test this hypothesis, the mouth of each patients, upon initial evaluation, were divided in 2 parts: before a session of nonsurgical supportive therapy in half mouth the test sites (probing depth > 5 mm or 5 mm with bleeding on probing) are treated with a traditional handpiece (control group) in the other half mouth the test sites are treated with an innovative handpiece which carries hydroxyapatite (test group).
The prevalence of residual pockets will be evaluated at 6 weeks, 3 and 6 months after the initial therapy and compared between the two groups.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Brescia, Lombardy, 25123, Italy
TRIAL DESIGN:
A prospective, single-masked, randomized, split-mouth, longitudinal clinical trial.
POPULATION Forty-four (44) adults, aged 18-75 years, will be entered into study (randomized). It is expected that forty (40) subjects will complete the study.
Randomized subjects who deviate from the protocol (major protocol deviation) and, for this reason, are excluded from the analysis, will be replaced to guarantee that the sample required for the analysis (40) is reached.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test group receives debridement with Vector PARO handpiece with hydroxyapatite for 30 seconds. The presence of fluid containing hydroxyapatite associated with ultrasonic allows the root biofilm to be broken down thanks to cavitation and hydrodynamic forces.
Control group receives a traditional ultrasonic debridement for remove supra and sub gingival biofilm and calculus for 30 seconds
Time frame: 6 months after initial therapy.
Change in mean PD value for each patient measured (from the gingival margin to the bottom of the pocket). Baseline values will be compared to the values recorded in the follow-up visits.
Time frame: 6 months after initial therapy
The number of experimental sites (PPD > 5mm or = 5 with BOP) becoming closed pockets (PPD ≤ 4mm).
Time frame: 6 months after initial therapy.
Change in mean of REC value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
Time frame: 6 months after initial therapy.
Change in mean of CAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.
Time frame: 6 months after initial therapy.
Change in percentage of sites positive to bleeding on probing. Baseline values will be compared to the values recorded in the follow-up visits.
Time frame: 6 months after initial therapy.
Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits.
Time frame: 6 months after initial therapy.
Changes on the VAS scale (1(less)-10(more)) of dentin hypersensitivity. Baseline values will be compared to the values recorded in the follow-up visits.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Other
Clinical Efficacy of Vector Paro With Hydroxyapatite in the Supportive Therapy of Periodontitis: a 6 Months Randomized Controlled Trial Study
Acronym: PAROXY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04422184
Dentin Hypersensitivity, Dentin Sensitivity
Bauru, São Paulo, Brazil
View Trial DetailsNCT02461030
Dentin Sensitivity, Mouth Diseases
Piracicaba, São Paulo, Brazil
View Trial DetailsNCT07642037
Dental Deposits, Dental Plaque
Sibiu, Sibiu County, Romania
View Trial DetailsNCT07697209
Alveolar Bone Loss, Bone Diseases
Al Mansurah, Egypt
View Trial Details